{{item.videoDuration}}
{{item.title}}
{{item.videoDuration}}
As well as an overview of the general transaction environment in the Swiss Health Industries sector, the publication delivers comprehensive insights into the past and current valuation levels of eleven sub-sectors (Big Pharma, Biotech, Consumer Health/OTC, Core MedTech, CRO/CDMO, Dental, Diagnostic Services, Digital Health, Elderly and Specialist Care, Generics and Hospitals) covering the entire Swiss Health Industries market, as well as sector-specific growth rates and margins.
Current M&A environment in the Health Industries sector
September 2025
Global Health Industry deal activity has slowed in recent years, with a decline in both deal volumes and values following a brief rebound earlier in 2025. In contrast, the Swiss health sector has shown resilience, supported by strong buyer demand and a growing role of private equity and financial investors, who now account for the majority of transactions.
Know more about the sectors
Big Pharma Core MedTech Diagnostic Services Generics |
Biotech CRO/CDMO Digital Health Hospitals |
Consumer Health/OTC Dental Elderly and Specialist Care |
Past reports
December 2024
Despite year-on-year declines in global Health Industries deal making, the Swiss M&A market has remained relatively resilient with cross-border activity rising to near 4-year highs. Several positive signals are apparent, nevertheless for now we are still waiting for the catalyst to start the next rally.
June 2024
The Swiss Health Industries market experienced a consistently high volume of deals in 2023 and throughout the first quarter of 2024. This robust deal activity can be attributed to the strong participation of financial sponsors and the notable presence of cross-border transactions within the sector, highlighting the international importance of the Swiss Health Industries market. Despite the challenging M&A market across various industries, the Health Industries sector remains attractive for both buyers and sellers due to its anti-cyclical nature. Swiss health companies, being at the forefront of industry trends, are expected to prioritise optimising their capabilities and pursuing inorganic growth opportunities.
Swiss M&A Report
Market and valuation update for the Health Industries sector
{{filterContent.facetedTitle}}
{{contentList.loadingText}}
{{contentList.loadingText}}
